Resources
Resources for Medical Professionals
Cancer.net. Skin cancer (non-melanoma). https://www.cancer.net/cancer-types/skin-cancer-non-melanoma
Cancer.org. Basal and squamous cell skin cancer. https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer.html
Skin Cancer Foundation. Basal cell carcinoma overview. https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/
Memorial Sloan Kettering Cancer Center. Basal Cell Carcinoma. https://www.mskcc.org/cancer-care/types/basal-cell-carcinoma
American Academy of Dermatology Association. Skin Cancer Types. Basal Cell Carcinoma Overview. https://www.aad.org/public/diseases/skin-cancer/types/common/bcc
Treatment Recommendations
American Academy of Dermatology Association. Skin Cancer Types. Basal Cell Carcinoma Diagnosis and Treatment. https://www.aad.org/public/diseases/skin-cancer/types/common/bcc/treatment
National Cancer Center Network. NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. Version 1.2022 – November 17, 2021. https://www.nccn.org/patients/guidelines/content/PDF/basal-cell-patient-guideline.pdf
Work Group; Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of basal cell carcinoma. J Amer Acad Derm. 2018;78:540-559. https://www.jaad.org/article/S0190-9622(17)32529-X/fulltext
NIH. National Cancer Institute. Skin Cancer Treatment (PDQ®)–Health Professional Version. Updated February 11, 2022. https://www.cancer.gov/types/skin/hp/skin-treatment-pdq
Journal Articles
Bassett-Seguin N, Herms F. Update in the Management of Basal Cell Carcinoma. Acta Derm Venereol. 2020;100:adv00140. https://pubmed.ncbi.nlm.nih.gov/32346750/
Chen D, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013;39:1-10. https://pubmed.ncbi.nlm.nih.gov/23890059/
Jayaraman S, Rayhan D. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol. 2014;134:213-220. https://pubmed.ncbi.nlm.nih.gov/23774526/
Kim D, Bus K, Ruiz E. Basal cell carcinoma review. Hematol Oncol Clin North Am. 2019;33:13-24. https://pubmed.ncbi.nlm.nih.gov/30497670/
Lewis K, Perris K. Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs). SKIN J Cutaneous Med. 2021;5(1):s3. https://jofskin.org/index.php/skin/article/view/1155
Morgan F, Ruiz E. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter. J Am Acad Dermatol. 2020;83:832-838. https://pubmed.ncbi.nlm.nih.gov/31600531/
Naik P, Desai M. Oncol Ther. Basal Cell Carcinoma: A Narrative Review on Contemporary Diagnosis and Management. 2022;10(2):317-335. https://pubmed.ncbi.nlm.nih.gov/35729457/
Sekulic A, Migden M. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72:1021-1026.e8. https://pubmed.ncbi.nlm.nih.gov/25981002/
Villani A, Potestio L, Fabbrocini G, et al. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma. Adv Ther. 2022;39(3):1164-1178. https://pubmed.ncbi.nlm.nih.gov/35089534/
